Cure8 news brief
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
For people on or considering these drugs, the findings could affect prescribing patterns and coverage decisions over time.
Adults with Crohn's disease or ulcerative colitis, patients on or considering biologic/JAK therapy, clinicians treating IBD, and researchers or payers following real-world effectiveness and formulary positioning.
The piece is an investor-oriented summary of DDW data rather than a clinical report. It highlights that real-world evidence and longer-term outcomes were presented for SKYRIZI (risankizumab) and RINVOQ (upadacitinib) in Crohn's disease and ulcerative colitis, and suggests these data could affect prescribing, payer coverage, and AbbVie's market position.
It does not provide detailed study methods, patient counts, or specific efficacy/safety results. If you want to learn more: look for the original DDW abstracts or peer-reviewed reports referenced by AbbVie for full clinical details, and check guideline or regulatory updates before considering changes to care.
This is an investor-facing summary referencing DDW presentations; it does not replace reading original study abstracts or regulatory filings. Reported real-world benefits and regulatory filings (e.g., subcutaneous induction for SKYRIZI) require confirmation in full data releases and guideline updates before changing clinical care.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.
A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...
